A Medicare Advantage denial lawsuit is a class action claim challenging insurance companies’ decisions to deny or limit coverage for medically necessary care under Medicare Advantage plans. The most prominent example involves UnitedHealth, where a federal court ruled on February 13, 2025, that patients can proceed with a class action alleging the company’s AI algorithm has a 90% error rate in determining whether care is medically necessary. These lawsuits represent a growing movement to hold Medicare Advantage insurers accountable for systematic claim denials that often contradict medical judgment and override doctors’ recommendations.
Medicare Advantage plans, which are privatized alternatives to traditional Medicare, have come under intense legal scrutiny for their denial practices. Multiple lawsuits filed across the country allege that insurers deliberately use flawed automated systems and overly restrictive guidelines to deny claims, reducing their medical costs while harming patients. The stakes are significant: these denials delay or prevent seniors from receiving medications, hospital stays, physical therapy, and other critical treatments.
Table of Contents
- What are the major Medicare Advantage denial lawsuits currently pending?
- How are AI algorithms being used to deny Medicare Advantage claims?
- What do the numbers reveal about Medicare Advantage denial rates?
- Why are appeals so important, and why don’t more patients pursue them?
- What is the financial and clinical impact on healthcare providers?
- What should patients know about the claims appeals process?
- What does the future hold for Medicare Advantage oversight and litigation?
- Conclusion
What are the major Medicare Advantage denial lawsuits currently pending?
The largest and most closely watched case involves Unitedhealth Group and its subsidiary UnitedHealthcare. In Estate of Gene B. Lokken et al. v. UnitedHealth Group Inc., filed in U.S.
District Court for the District of Minnesota, plaintiffs allege that UnitedHealth’s AI model fails to accurately determine medical necessity nearly 90% of the time. The court’s February 2025 ruling means the case can proceed as a class action on state law claims including breach of contract and breach of the implied covenant of good faith and fair dealing—a significant victory for patients because it means the Medicare Act does not preempt these broader legal claims. Humana, another major Medicare Advantage carrier, faces similar allegations involving its proprietary algorithm called “nH Predict.” The lawsuit claims Humana uses this AI model to improperly deny care to elderly Medicare Advantage patients, often overriding physician orders. Additionally, Ballad Health, a regional health system, filed a federal lawsuit against UnitedHealth alleging the company has “systematically abused and manipulated” Medicare Advantage practices. According to Ballad’s filing, UnitedHealth’s denials of post-acute care access have cost Ballad over $65 million in the last five years alone—illustrating how widespread the financial consequences extend beyond individual patients to entire health systems.
How are AI algorithms being used to deny Medicare Advantage claims?
Insurance companies have increasingly deployed artificial intelligence and machine learning models to automate coverage decisions, ostensibly to improve efficiency and reduce fraud. However, plaintiffs argue these systems are fundamentally flawed. UnitedHealth’s algorithm, for instance, allegedly assigns risk scores to patients and uses those scores to automatically deny or delay claims without human review by clinicians familiar with the patient’s medical history. The 90% error rate allegation suggests the algorithm denies care that should have been approved according to medical standards and the patient’s coverage plan.
The problem is compounded by the lack of transparency. Most patients and their doctors don’t know which specific algorithm reviewed their claim or what factors the algorithm weighted in its decision. When a claim is denied, the explanation often cites “medical necessity guidelines” without revealing that a machine made the determination or allowing meaningful human appeal. Humana’s “nH Predict” model similarly operates as a black box, with limited disclosure to patients about how their individual risk profile influences claim decisions. This automation bypasses the clinical judgment that traditionally guided coverage decisions, creating a scenario where algorithms override doctors’ treatment recommendations without their knowledge.
What do the numbers reveal about Medicare Advantage denial rates?
The denial statistics paint a stark picture of systemic overclaiming by Medicare Advantage insurers. Medicare Advantage plans deny 17% of initial claims, compared to only 8% for traditional Medicare—a gap that suggests deliberate differences in coverage policy rather than random variation. This disparity is particularly troubling because Medicare Advantage enrollees are a vulnerable population: seniors who have chosen these plans are often sicker or more cost-conscious than those in traditional Medicare, and they’re less likely to have the resources to fight denials. The financial impact has grown sharply.
In 2024, the average denied claim amount reached approximately $1,000, representing a 22.4% increase from the prior year. Medicare Advantage insurers processed nearly 53 million prior authorization requests in 2024 alone, demonstrating the sheer scale of denial decisions. Denial rates themselves have climbed 4.8% from 2023 to 2024, with rates continuing to rise in 2025 as insurers implement stricter payer guidelines and increase automation. This upward trajectory suggests the problem is accelerating rather than stabilizing.
Why are appeals so important, and why don’t more patients pursue them?
One of the most counterintuitive findings in Medicare Advantage litigation is that 80.7% of appealed prior authorization denials are ultimately overturned—meaning insurers get these denials wrong more than four times out of five. This extraordinarily high appeal success rate proves that the initial denial decision was incorrect and should never have been made. However, only 11.5% of patients with denied claims actually appeal. The reasons are clear: patients must navigate complex appeal procedures while sick or injured, often without legal help, and many don’t even know they have the right to appeal.
The appeal process itself is broken. Patients typically have a limited window to request review, must gather medical records, and must articulate why the insurer’s decision contradicts medical standards. Many seniors lack the technical skills or mental energy to undertake this challenge while recovering from illness or injury. Insurance companies are well-aware of this dynamic—the low appeal rate means they profit from denials that would be reversed if patients had the time and resources to challenge them. class action litigation aims to shift this burden back onto the insurers by making them defend their blanket denial practices rather than counting on patient inertia to absorb the losses.
What is the financial and clinical impact on healthcare providers?
The denial crisis extends far beyond individual patients to destabilize the entire healthcare delivery system. Nursing home and post-acute care providers report that Medicare Advantage denial rates have cut their revenues by 7%—a significant loss for facilities operating on thin margins. Ballad Health’s $65 million loss over five years reflects the aggregate damage across a large health system, but even smaller providers feel the squeeze. When claims are denied, providers must write off the charges or pursue lengthy appeals themselves, diverting staff and resources from patient care. The clinical consequences are equally severe.
Providers report that Medicare Advantage denials delay patients’ access to rehabilitation, wound care, skilled nursing services, and other post-acute treatments. This not only extends recovery times but can result in worse long-term health outcomes, hospital readmissions, and additional complications. A patient denied post-acute physical therapy after hip replacement surgery may develop permanent mobility limitations. A patient denied a medically necessary medication may suffer preventable health deterioration. Providers have become de facto advocates for patients, forced to spend hours appealing denials and justifying medically necessary care to algorithms and insurance reviewers with no direct knowledge of the patient.
What should patients know about the claims appeals process?
Patients with denied Medicare Advantage claims have the right to appeal, and the statistics suggest appeals are worth pursuing given the high overturn rate. The standard appeals process begins with a request for reconsideration within 60 calendar days of the denial notice. Patients should submit any additional clinical information, doctor’s notes, or supporting evidence that addresses the reason for the initial denial. If the claim involves urgent or emergent services, patients can request an expedited appeal, which must be reviewed within 72 hours rather than the standard 30 days for non-urgent claims.
If the first level of appeal is denied, patients can request an independent external review. This review is conducted by a third-party review organization contracted by the insurance company but obligated to make an independent clinical determination. External reviewers have expertise in the relevant medical field and are more likely to reverse denials based on clinical evidence rather than algorithmic flags. Patients should save all correspondence, document dates of conversations, and keep records of how the denial affected their health or care. For complex cases or large claim amounts, consulting with an attorney experienced in Medicare Advantage disputes can significantly improve outcomes.
What does the future hold for Medicare Advantage oversight and litigation?
The February 2025 federal court ruling in the UnitedHealth case signals that judges are willing to hold Medicare Advantage insurers accountable through class action litigation. By allowing state law claims to proceed alongside federal Medicare claims, the court has opened a broader pathway for patients to seek damages for breach of contract and violations of the implied covenant of good faith and fair dealing. This ruling may inspire additional lawsuits and could encourage regulatory agencies to scrutinize insurer practices more closely.
The broader trend suggests increased regulatory pressure on Medicare Advantage plans. Federal authorities, state attorneys general, and Congress are all examining whether these plans are systematically exploiting their networks and benefit designs to deny coverage. If courts continue to rule that AI-driven denials can be challenged through class actions, and if more health systems file suits like Ballad Health’s, the litigation landscape could fundamentally reshape how Medicare Advantage insurers operate. The pending cases will determine whether algorithmic denial systems must be disclosed, validated, and audited before deployment—or whether they can continue operating as opaque black boxes that override physician judgment.
Conclusion
Medicare Advantage denial lawsuits represent a critical moment in the evolution of healthcare litigation. They challenge not just individual wrongful denials but entire systems designed to systematically reduce claims approval rates through automation, lack of transparency, and procedural barriers that discourage appeals. The evidence—from the 90% error rate allegation in the UnitedHealth case to the $65 million impact on Ballad Health—demonstrates that these are not isolated mistakes but structural problems built into how major insurers process claims.
If you or a loved one has had a Medicare Advantage claim wrongfully denied, consider requesting an appeal immediately given the high overturn rates. For patients interested in joining a class action lawsuit or learning whether you have a claim, consult with an attorney who specializes in Medicare Advantage disputes. The outcomes of cases currently pending in federal court will shape whether Medicare Advantage insurers must reform their practices or whether they can continue prioritizing algorithmic denial systems over patient access to medically necessary care.